AGPS and systemic lupus erythematosus: These ADAs were still above the disease-specific cut-point established according to internationally established recommendations [32] and suggest the presence of naturally occurring antibodies, which in turn, should reflect the intrinsic B cell hyperreactivity typical of SLE and the presence of a remarkably broad antibody repertoire.